Edition:
United Kingdom

Aveo Pharmaceuticals Inc (AVEO.OQ)

AVEO.OQ on NASDAQ Stock Exchange Capital Market

2.53USD
18 Oct 2018
Change (% chg)

-- (--)
Prev Close
$2.53
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
511,236
52-wk High
$3.58
52-wk Low
$1.86

Chart for

About

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI)... (more)

Overall

Beta: 1.22
Market Cap(Mil.): $454.30
Shares Outstanding(Mil.): 118.31
Dividend: --
Yield (%): --

Financials

  AVEO.OQ Industry Sector
P/E (TTM): -- 85.83 33.69
EPS (TTM): -0.56 -- --
ROI: -166.61 0.58 14.30
ROE: -- 1.62 16.03

BRIEF-Aveo Reports Q1 Loss Per Share $0.08

* AVEO REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

08 May 2018

Competitors

  Price Chg
DAIICHI SANKYO COMPANY, LIMITED (4568.T) ¥4,532 +22.00
Eisai Co., Ltd (4523.T) ¥10,795 +245.00
Pfizer Inc. (PFE.N) $44.00 -0.57
Novartis AG (NOVN.S) CHF86.32 +0.44
Roche Holding Ltd. (ROG.S) CHF240.90 +2.35
Roche Holding Ltd. (RO.S) CHF242.00 +2.60
Bayer AG (BAYGn.DE) €77.67 -0.75
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €77.62 -0.18
AstraZeneca plc (AZN.L) 5,904.00 +26.00

Earnings vs. Estimates